Tenderwize
Retour à la recherche

Open-house non-exclusive rebate agreement for Fusidinsäure/Betamethason

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Jul 31, 2027 · 337 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Titre original de l'avis

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Fusidinsäure/Betamethason (ATC-Code nach WHO: D07CC01)

46/100

Score d'opportunité

Needs reviewMedium complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

46 / 100

Complexité

58 / 100

Facteurs de risque

Demand is explicitly unknown and depends on prescriptions, insured population development, and pharmacy stocking behavi...

The notice says the publication form contains technical placeholder fields with no substantive meaning for this Open-Ho...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Jul 2027
  • Non-exclusive rebate agreement for pharmaceutical products containing Fusidinsäure/Betamethason.
  • Open-House participation model with equal access for all interested qualifying pharmaceutical companies.
Afficher le résumé complet

This is an Open-House pharmaceutical supply arrangement for Fusidinsäure/Betamethason (ATC D07CC01) led by AOK PLUS. It is non-exclusive, open to all qualifying pharmaceutical companies, with no individual negotiations and no guaranteed minimum purchase volume. Participation documents are available via DTVP, but the extracted procurement documents were not provided beyond the XML notice text, so document-specific instructions cannot be fully verified.

Risques

Demand is explicitly unknown and depends on prescriptions, insured population development, and pharmacy stocking behavi...

The notice says the publication form contains technical placeholder fields with no substantive meaning for this Open-Ho...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Applicant must be a pharmaceutical company within the meaning of § 4(18) AMG for the offered medicinal product.
  • The company must accept the participation conditions and the rebate agreement terms.

Eligibility

  • Submission of the completed declaration of non-existence of exclusion grounds is required.

Acheteur

Localisation

Erfurt, DEU

Profil acheteur

Ouvrir le profil

Identifiant

DE256878834

Activité

Health

Lots (1)

LOT-0001

Open-house non-exclusive rebate agreement for Fusidinsäure/Betamethason

Supply lot for non-exclusive pharmaceutical rebate agreements under § 130a(8) SGB V for the active substance Fusidinsäure/Betamethason (ATC D07CC01). The lot is an Open-House model, so any interested qualifying pharmaceutical company may join during the participation period. No exclusivity, no individual negotiations, and no guaranteed minimum purchase volume are stated. Performance/place of performance is Germany, specifically Dresden in the structured data.

SuppliesFrameworkEU fundedElectronic submission

Localisation

Dresden, Germany

Durée

Jul 2025 - Jul 2027

Catégorie

Pharmaceutical products

Date limite

Deadline Jul 31, 2027

Détails de la procédure

Date de publication
21 May 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
330350-2025

Documents (1)

Document de consultation 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30